

JANUARY 2005 DUR BOARD MEETING MINUTES

Date: January 26, 2005

Members Present: Eichler, Nagy, Fitzgerald, Sargent, Bradley, Brown, Crichton, Burton, Cobb (phone in)

Others Present: Peterson, Preshinger, Citron (Medicaid), Barnhill, Wilkinson (Drug PA), Ken Kolb and Dawn Daly (First Health), Interested members of the public and representatives of pharmaceutical manufacturers.

Mark Eichler opened the meeting with a review of meeting procedure. The public meeting today will be followed by an executive session of the Board which is not open to the public. The board has some appeal letters and case sensitive issues to discuss. At that time all members of the public will be asked to leave. Before beginning the PDL program today, the Board will address the issue of PA criteria for the new drug Lunesta.

Board Minutes: The minutes of the December meeting were reviewed with Mark asking the Board members to pay special attention to the PDL discussion results. The minutes were approved.

Department update:

Dan Peterson, Pharmacy Program Officer for DPHHS updated the board on the following:

The Department has received approval for the state plan from CMS, the federal Medicaid agency. The Preferred Drug List implementation has begun.

Roger Citron, Pharmacist for DPHHS added the following:

The PDL roll out schedule is posted on the Department web site, which is mtmedicaid.org. The Department has planned education programs around the state to help the transition to the PDL. These dates and locations are also on the web site. Roger also brought along copies of the roll out schedule as well as the DPHHS Preferred Drug List (PDL) Position Statement which were made available. The Position Statement is also available on the web site. It addresses the issues of new drugs and drug manufactures marketing with regard to the PDL. New drugs will be considered non-preferred until reviewed. All classes will be reviewed annually and may, at the Department's discretion, be reviewed sooner. The Department is taking the position that drugs may not be marketed as preferred without authorization from the Department.

Board Meeting:

Lunesta, a new sedative/hypnotic agent is now available. The other non-generic sleeping agents on the market, Ambien and Sonata, are available to Medicaid patients with Prior Authorization. The criteria for approval is failure on two multi-source sleep aids. Medicaid only covers 15 doses per month. Ambien and Sonata are approved only for short term therapy for insomnia. Lunesta has some documentation supporting use in chronic insomnia. At this time there is only one long term use study, so the Board decided at this time to put Lunesta in the same category as Ambien and Sonata, with the same PA requirements and monthly limits. This issue will be reviewed at a later meeting when more information is available.

Preferred Drug List Discussion:

The following drug classes were considered and outcomes determined by review of the evidence, public comment, and board discussion.

LONG ACTING NARCOTICS:

Must add: one long acting morphine OR long acting oxycodone

May add: Duragesic, Pallidone, Avinza, Kadian

Patients will be **grandfathered** on current therapy.

PEGYLATED INTERFERONS/RIBAVIRINS:

TOPICAL IMMUNOMODULATORS:

INHALED ANTICHOLINERGIC AGENTS:

Must add:

May add:

URINARY ANTISPASMODICS:

Executive Session:

Next meeting is February 16, 2005 at The MACO Building meeting room in Helena.

Meeting adjourned at 4:30.